StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Wedbush Upgrades Sarepta Therapeutic (SRPT) to Outperform, $36 PT
June 7, 2016 6:40 AM
Wedbush upgraded Sarepta Therapeutic (NASDAQ: SRPT) from Neutral to Outperform with a price target of $36.00 (from $14.00), as FDA ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Analyst PT Change
FDA
Hot Upgrades
Upgrades
Next Articles
Piper Jaffray Remains Negative on Sarepta (SRPT), 'Unable to Handicap Chances for AA'
June 7, 2016 9:08 AM
Jefferies Continues to See Low Probablity of Sarepta (SRPT) Approval
June 7, 2016 7:50 AM
Sarepta (SRPT): Accelerated Approval Seen Pending Dystrophin Data Analysis - Oppenheimer
June 7, 2016 6:49 AM
Sarepta (SPRT): FDA Request for Dystrophin Data a 'Clear Indication Willing to Grant Accelerated Approval' - Baird
June 7, 2016 6:25 AM
Amid Dystrophin Data Request, Uncertainty Remains in Sarepta (SRPT) - Leerink
June 7, 2016 6:16 AM
Sarepta Therapeutics (SRPT) Surges as FDA Requests Dystrophin Data for eteplirsen NDA
June 6, 2016 5:45 PM
Sarepta Therapeutics (SRPT) Says FDA Requests Dystrophin Data
June 6, 2016 5:41 PM
